deltatrials
Unknown PHASE2 INTERVENTIONAL 3-arm NCT02858921

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma (Neo Trio)

A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma

Sponsor: Melanoma Institute Australia

Conditions Melanoma
Interventions Dabrafenib Pembrolizumab Trametinib
Updated 19 times since 2017 Last updated: Aug 28, 2023 Started: Nov 8, 2017 Primary completion: Jan 2, 2022 Completion: Nov 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02858921, this PHASE2 trial focuses on Melanoma and remains ongoing. Sponsored by Melanoma Institute Australia, it has been updated 19 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~May 2019 · 5 months · monthly snapshot~May 2019 – ~Nov 2019 · 6 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2023 · 15 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2025 · 13 months · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded

  1. Oct 2025 — Present [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2024 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  5. Jan 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  7. May 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  8. Dec 2018 — May 2019 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  10. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Jun 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE2

  12. Apr 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

  13. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Melanoma Institute Australia
  • Merck Sharp & Dohme LLC
  • Novartis
Data source: Melanoma Institute Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations